

APPENDIX
AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

Claims 1-25 (Canceled).

Please insert new Claims 26-41:

Claim 26 (New): An isolated and purified *Sarcocystis neurona* strain designated SNg, having ATCC Accession No. PTA-2972 or a subculture thereof.

Claim 27 (New): An immunogenically active component useful for preventing or ameliorating equine protozoal myoencephalitis disease which comprises merozoite antibody-inducing whole cells of a *Sarcocystis neurona* isolate designated SNg, having ATCC Accession No. PTA-2972 or a subculture thereof.

Claim 28 (New): The immunogenically active component according to Claim 27 wherein the whole cells of the *Sarcocystis neurona* isolate or the subculture thereof are inactivated.

Claim 29 (New): The immunogenically active component according to Claim 28 wherein the whole cells of the *Sarcocystis neurona* isolate or the subculture thereof are present in sufficient quantity to provide at least 1×10^4 inactivated cells per dosage unit form.

Claim 30 (New): A vaccine composition for the prevention or amelioration of equine protozoal myoencephalitis disease in an equine which comprises a therapeutically effective amount of the immunogenically active component of Claim 28, a pharmacologically acceptable carrier and optionally an immunogenically stimulating adjuvant.

Claim 31 (New): The vaccine composition according to Claim 30 wherein said active component is present in sufficient quantity to provide at least 1×10^4 inactivated cells per dosage unit form.

Claim 32 (New): The vaccine composition according to Claim 30 wherein said active component is present in sufficient quantity to provide at least 1×10^6 inactivated cells per dosage unit form.

Claim 33 (New): The vaccine composition according to Claim 30 wherein said active component is present in an amount sufficient to produce a merozoite inducing serum neutralizing antibody response which has a neutralizing effect on *Sarcocystis neurona* merozoites.

Claim 34 (New): The vaccine composition according to Claim 30 wherein the immunogenically stimulating adjuvant is present at about 1% to 50% by weight.

Claim 35 (New): The vaccine composition according to Claim 34 wherein said adjuvant is present at about 5% to 20% by weight.

Claim 36 (New): The vaccine composition according to Claim 34 wherein said adjuvant is a metabolizable oil.

Claim 37 (New): The vaccine composition according to Claim 36 wherein the pharmacologically acceptable carrier is a balanced salt solution.

Claim 38 (New): A method for the prevention or amelioration of equine protozoal myoencephalitis disease in an equine which comprises administering to said equine the immunogenically active component of Claim 28.

Application No. 09/840,485
Group Art Unit 1645

Claim 39 (New): A method for the prevention or amelioration of equine protozoal myoencephalitis disease in an equine which comprises administering to said equine a therapeutically effective amount of the vaccine composition of Claim 30.

Claim 40 (New): The method according to Claim 39 wherein said vaccine is administered parenterally.

Claim 41 (New): The method according to Claim 39 wherein said vaccine is administered intramuscularly.